Table 1. Baseline patient characteristics.
| Characteristic | Melanoma Expansion Cohort (n=26) | Entire Study Population (N=77) |
|---|---|---|
| Age, ya | ||
| Mean (SD) | 65.5 (11.66) | 61.3 (12.85) |
| Median | 69.0 | 61.0 |
| Range (min, max) | (38, 85) | (28, 85) |
| Sex, n (%) | ||
| Male | 16 (61.5) | 40 (51.9) |
| Female | 10 (38.5) | 37 (48.1) |
| Race, n (%) | ||
| Non-Hispanic White | 26 (100) | 64 (83.1) |
| Hispanic | 0 | 9 (11.7) |
| African-American | 0 | 4 (5.2) |
| ECOG status, n (%) | ||
| 0 | 8 (30.8) | 30 (39.0) |
| 1 | 17 (65.4) | 45 (58.4) |
| 2 | 1 (3.8) | 2 (2.6) |
| Tumor type, n (%) | ||
| Colorectal | 0 | 10 |
| Thyroid | 0 | 6 |
| Ovarian | 0 | 5 |
| Endometrial | 0 | 4 |
| Breast | 0 | 3 |
| Melanoma | 26 (100) | 3 |
| Lung | 0 | 2 |
| Pancreatic | 0 | 2 |
| Prostate | 0 | 2 |
| Other | 0 | 14 |
| Previous anticancer treatment, n (%) | ||
| Chemotherapy | 22 (84.6) | 70 (90.9) |
| Radiotherapy | 13 (50.0) | 42 (54.5) |
| Surgery | 26 (100) | 77 (100.0) |
| Other anticancer treatment regimens | 18 (69.2) | 47 (61.0) |
| Previous systemic treatment (chemotherapy), n (%) | ||
| 0 | 4 (15.4) | 7 (9.1) |
| 1 | 8 (30.8) | 19 (24.7) |
| 2 | 9 (34.6) | 25 (32.5) |
| ≥3 | 5 (19.2) | 26 (33.8) |
| Mutation statusb, n (%) | ||
| BRAF | 9 (34.6) | ― |
| NRAS | 8 (30.8) | ― |
a
Age calculated as (date of informed consent – date of birth + 1)/365.25.
b
Mutations were assessed only in patients in the melanoma expansion cohort.
Abbreviation: SD, standard deviation.